# Onesource Specialty Pharma (NSE: ONESOURCE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ONESOURCE · Pivot · prices to 22 Oct 2026

Onesource Specialty Pharma (NSE: ONESOURCE) closed at ₹1,378.00 on 22 Oct 2026, up 1.64% on the day. With a market capitalisation of ₹15,796 Cr, it ranks 404th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was −1.3% in FY26. Over the past year the share price has fallen 25.1%. Its 52-week range is ₹1,057.00 (30 Jan 2026) to ₹1,925.00 (3 Nov 2025); the last close is 28.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹449 Cr (+37.2% year on year) and net profit ₹25 Cr, on a consolidated basis. Promoters held 30.48% of the company as of 30 Jun 2026; 37.23% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,378.00 |
| Market cap | ₹15,796 Cr |
| ROE | −1.3% (FY26) |
| ROCE | 0.6% (FY26) |
| Debt to equity | 0.22 |
| 52-week high | ₹1,925.00 (3 Nov 2025) |
| 52-week low | ₹1,057.00 (30 Jan 2026) |
| 1-year return | −25.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹449 Cr | +37.2% | ₹25 Cr | — | ₹2.18 |
| Q4 FY26 | ₹428 Cr | +0.5% | ₹5 Cr | −95.3% | ₹0.40 |
| Q3 FY26 | ₹290 Cr | −26.0% | −₹89 Cr | — | −₹7.74 |
| Q2 FY26 | ₹376 Cr | +12.5% | ₹10 Cr | — | ₹0.92 |
| Q1 FY26 | ₹327 Cr | +12.0% | −₹0 Cr | — | −₹0.02 |
| Q4 FY25 | ₹426 Cr | +482.4% | ₹99 Cr | — | ₹8.61 |
| Q3 FY25 | ₹393 Cr | +598.4% | −₹69 Cr | — | −₹6.31 |
| Q2 FY25 | ₹334 Cr | — | −₹42 Cr | — | −₹3.89 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,445 Cr | −₹18 Cr |
| FY24 | ₹172 Cr | −₹391 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 30.48%
- Foreign institutions: 19.19%
- Domestic institutions: 23.38%
- Non-institutions: 26.94%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Shilpa Medicare](https://app.pivotnow.in/stock/SHILPAMED) | ₹880.90 | ₹16,836 Cr | 70.9 | 9.4% |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,576 Cr | 27.7 | 17.2% |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,537 Cr | 25.3 | 15.9% |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,357 Cr | 22.9 | 11.2% |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,056.00 | ₹15,252 Cr | 80.9 | 15.0% |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹370.75 | ₹15,037 Cr | 47 | 6.5% |

## Questions and answers

### What is the share price of Onesource Specialty Pharma today?

Onesource Specialty Pharma (NSE: ONESOURCE) last closed at ₹1,378.00 on 22 Oct 2026. Its 52-week high is ₹1,925.00 and its 52-week low is ₹1,057.00.

### What is the market cap of Onesource Specialty Pharma?

Onesource Specialty Pharma's market capitalisation is ₹15,796 Cr (₹15,796 Cr) at the 22 Oct 2026 close, ranking 404th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Onesource Specialty Pharma?

Return on equity was −1.3% in FY26 and return on capital employed was 0.6% in FY26 (consolidated figures).

### Is Onesource Specialty Pharma a debt-free company?

No. Onesource Specialty Pharma's debt-to-equity ratio was 0.22 in FY26, with total debt of ₹564 Cr.

### What were Onesource Specialty Pharma's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Onesource Specialty Pharma reported revenue of ₹449 Cr, +37.2% year on year, and net profit of ₹25 Cr.

### How has Onesource Specialty Pharma stock performed over the last year?

Onesource Specialty Pharma's share price has fallen 25.1% over the past year, −17.2% over three months and −13.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Onesource Specialty Pharma?

As of 30 Jun 2026: promoters 30.48%, foreign institutions 19.19%, domestic institutions 23.38%, non-institutions 26.94%. 37.23% of promoter shares were pledged.

### Who are Onesource Specialty Pharma's competitors?

The listed Pharma & Healthcare companies closest to Onesource Specialty Pharma by market cap are Shilpa Medicare, Alivus Life Sciences, Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India and Syngene International.

### Is Onesource Specialty Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Onesource Specialty Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ONESOURCE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.